Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20542591 | 0.83 | — | — | |
| SCHEMBL1832902 | 0.74 | MAPT (0.38) | ALDH1A1TP53SMN1; SMN2NQO2KDM4E | |
| SCHEMBL212513 | 0.74 | MAPT (0.44) | GAAALDH1A1NQO2KDM4EMAPT | |
| SCHEMBL11782779 | 0.72 | NPC1 (0.31) | GAANPC1RAB9A | |
| SCHEMBL3144534 | 0.70 | NQO2 (0.43) | ALDH1A1TP53TSHRSMN1; SMN2NQO2 | |
| SCHEMBL391093 | 0.68 | KDM4E (0.41) | ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL9007893 | 0.68 | DRD2 (0.32) | — | |
| SCHEMBL2160767 | 0.66 | RAB9A (0.43) | ALDH1A1TP53CYP3A4SMN1; SMN2NQO2 | |
| SCHEMBL11122399 | 0.66 | SMN1; SMN2 (0.49) | GAAALDH1A1TP53TSHRSMN1; SMN2 | |
| SCHEMBL5345055 | 0.66 | FGFR1 (0.37) | ALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7626030-B2 | Compounds and methods of use | AMGEN INC. (US) | 2009-12-01 | — | — | US | claimed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | claimed |
| JP-2007518823-A | — | — | 2007-07-12 | — | — | JP | claimed |
| JP-2007518824-A | — | — | 2007-07-12 | — | — | JP | claimed |
| US-20060241115-A1 | Compounds and methods of use | AMGEN INC. | 2006-10-26 | — | — | US | claimed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | claimed |
| EP-1711495-A2 | QUINOLINE, QUINAZOLINE, PYRIDINE AND PYRIMIDINE COUNDS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2006-10-18 | — | — | EP | claimed |
| US-20050245547-A1 | 6-((6,7-Bis(methoxy)-4-quinolinyl)oxy)-N-(3-methylphenyl)-1-benzofuran-3-carboxamide;antiproliferative; -metastasis; -carcinogenic; -tumor; -inflammatory; -arthritic agents;hypotensive agents; myocardium necrosis; rheumatic diseases; tyrosine kinase inhibitors; antiallergens; asthma | AMGEN INC. | 2005-11-03 | — | — | US | claimed |
| WO-2005073224-A2 | QUINOLINE QUINAZOLINE PYRIDINE AND PYRIMIDINE COUNDS AND THEIR USE IN THE TREATMENT OF INFLAMMATION ANGIOGENESIS AND CANCER | AMGEN INC (US) | 2005-08-11 | — | — | WO | claimed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | claimed |
| US-5310888-A | Calcium detection | MILES INC. (US) | 1994-05-10 | — | — | US | claimed |
| US-4259336-A | ANALGESIC, ANTIPYRETIC, ANTITHROMBOTIC, ANTIPHLOGISTIC | BOEHRINGER INGELHEIM GMBH (DE) | 1981-03-31 | — | — | US | claimed |
| EP-0009142-A1 | 4-Hydroxy-2H(1)benzothieno(2,3-e)-1,2-thiazine-3-carboxamide-1,1-dioxide derivatives and salts thereof, their use and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1980-04-02 | — | — | EP | claimed |
| EP-1887002-B1 | CARBOXAMIDE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-8895582-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8759374-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-4096115-A | Ultraviolet light stabilized polymers | EASTMAN KODAK COMPANY (US) | 1978-06-20 | — | — | US | disclosed |
| US-4065427-A | Polychromophoric heterocyclic ultraviolet stabilizers and their use in organic compositions | EASTMAN KODAK COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-4017508-A | POLYMERS | EASTMAN KODAK COMPANY (US) | 1977-04-12 | — | — | US | disclosed |
| US-4000148-A | POLYMERS | EASTMAN KODAK COMPANY (US) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241115-A1 | Compounds and methods of use | HGF, HGFAC, MET | GAA 44/4885ALDH1A1 81/4885TP53 58/4885 |
| US-20050245547-A1 | 6-((6,7-Bis(methoxy)-4-quinolinyl)oxy)-N-(3-methylphenyl)-1-benzofuran-3-carboxamide;antiproliferative; -metastasis; -carcinogenic; -tumor; -inflammatory; -arthritic agents;hypotensive agents; myocardium necrosis; rheumatic diseases; tyrosine kinase inhibitors; antiallergens; asthma | HGF, MET, HGFAC | GAA 981/4885ALDH1A1 508/4885TP53 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.